The global spine osteoarthritis pain drug market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Osteoarthritis of spine is degeneration of cartilage of discs in lower back and neck. Sometimes osteoarthritis creates gaps that give pressure on nerves leaving the spinal column. Spinal osteoarthritis tends to occur more in older people as compared to younger ones. The factors resulting causes include injury, trauma to the spine or cartilage involved genetic defect. There are various forms of drugs available for spine osteoarthritis pain such as analgesics, that are used for pain treatment. This drug class works by stopping signals in the body that creates pain. Instances of analgesics include Acetaminophen (Tylenol) and Duloxetine (Cymbalta). Acetaminophen (Tylenol) is an over-the-counter (OTC) analgesic that can be administered orally as a tablet, gel capsule, or liquid concentration. Another class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs) is also used for the treatment of spine osteoarthritis pain. 

Some key players operating in the market include Pfizer Inc., Eli Lilly & Co., and GlaxoSmithKline plc, among others. These players are eyeing on strengthening their position in the market by adopting various strategies such as mergers and acquisitions, partnerships and collaborations, new product launches and development in the existing product portfolio, and so on. in March 2020, Pfizer and Eli Lilly and Company announced that FDA has accepted tanezumab 2.5 mg and given Biologics License Application (BLA). It was developed for treating patients with moderate-to-severe pain caused due to osteoarthritis. Additionally, tanezumab prevents pain signals produced by muscles, organs, and skin from reaching the brain and spinal cord.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Type
• By Distribution Channel

Regions covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape:  Pfizer Inc., Eli Lilly & Co., and GlaxoSmithKline plc, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Spine Osteoarthritis Pain Drug Market Report by Segment

By Type

• Oral
• Injection
• Others

By Distribution Channel

• Online
• Offline

Global Spine Osteoarthritis Pain Drug Market Report by Region

North America       

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific    

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East and Africa